Abstract: Scarring around the filtering bleb after glaucoma filtering surgery (GFS) is a major cause of surgical failure. The antimetabolic drug mitomycin-C (MMC) is the first-line treatment for scarring in GFS, but its cytotoxicity can lead to serious complications. Newer anti-scarring approaches include improved surgical techniques (e.g. creation of conjunctival flaps of varying depth), use of physical barriers to the filtration pathway (e.g. biodegradable collagen matrix implants, biodegradable collagen matrix implants, sodium hyaluronate, amniotic membranes, corneal stromal lenses and perfluoropropane gas), and anti-scarring drugs (glucocorticosteroids and non-steroidal anti-inflammatory drugs in addition to MMC, 5-fluorouracil and transforming growth factor-beta-regulating drugs, and the Chinese herbal medicines Dan Huayu Tang, glaucoma and granules, etc.), eye massage, β-radiation therapy, and so on.(Int Rev Ophthalmol, 2024, 48:   254-260)

Key words: glaucoma, filtration surgery, anti-scarring treatment